Full history for every metric is available with a Kvantra account
Vyant Bio, Inc. (VYNT)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 29 | 27 | 7 | 1 | 1 | 1 | 1 |
| Operating profit | $m | -16 | -16 | |||||
| Net profit | $m | -21 | -20 | -7 | -9 | -46 | -23 | -29 |
| EPS reported | $ | -3.87 | -4.89 | |||||
| Operating cashflow per share | $ | -2.33 | -2.33 | |||||
| Capex per share | $ | 0.11 | 0.11 | |||||
| FCF per share | $ | -2.44 | -2.44 | |||||
| Free cash flow | $m | -14 | -14 | |||||
| Net debt | $m | -8 | -10 | |||||
| Book value equity | $m | 10 | 10 | |||||
| Book value per share | $ | 1.69 | 1.68 | |||||
| Number of shares | m | 5.87 | 5.9 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.42 | 0.12 | |||||
| P/S LTM | x | 6.19 | 1.72 | |||||
| P/FCF LTM | x | -0.29 | -0.08 | |||||
| EV/EBITDA LTM | x | 0.25 | 0.60 | |||||
| EV/Sales LTM | x | -5.59 | -13.27 | |||||
| Earnings Yield LTM | % | -550.42% | -1993.2% | |||||
| FCF Yield | % | -346.85% | -1248.3% | |||||
| Quality | ||||||||
| ROE | % | -228.98% | -110.15% | |||||
| ROIC | % | -131.45% | -131.45% | |||||
| Operating margin | % | -2389.2% | -2389.2% | |||||
| Gross margin | % | -51.35% | -51.35% | |||||
| FCF/Sales | % | -2146.8% | -2146.8% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -41.99% | -41.99% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | -0.34% | |||||
| FCF/Debt | x | -6.51 | -6.51 | |||||
| Net Debt/EBITDA | x | 0.53 | 0.53 | |||||
| EBIT/Net interest | x | -171.10 | -171.10 | |||||
| Net debt/market cap | % | -190.31% | -871.68% | |||||
| Net debt/Equity | x | -0.79 | -1.01 | |||||
| Gross debt/equity | x | 0.22 | 0.22 | |||||
Company overview
Vyant Bio, Inc. is a biotechnology company focused on identifying treatments for intricate neurological conditions, including both neurodevelopmental and neurodegenerative disorders. The firm leverages a sophisticated central nervous system (CNS) drug discovery platform that integrates human-derived brain organoid models, high-throughput biological screening, and machine learning. Their primary goal is to pinpoint novel or existing small molecule drug candidates for rare genetic CNS diseases like Rett Syndrome, CDKL5 deficiency disorders, and hereditary forms of Parkinson's disease. Additionally, Vyant Bio, Inc. maintains a collaborative agreement specifically for the discovery of Parkinson's Disease therapies. The company's headquarters are located in Cherry Hill, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Vyant Bio, Inc. (VYNT)
Vyant Bio, Inc. is a biotechnology company focused on identifying treatments for intricate neurological conditions, including both neurodevelopmental and neurodegenerative disorders. The firm leverages a sophisticated central nervous system (CNS) drug discovery platform that integrates human-derived brain organoid models, high-throughput biological screening, and machine learning. Their primary goal is to pinpoint novel or existing small molecule drug candidates for rare genetic CNS diseases like Rett Syndrome, CDKL5 deficiency disorders, and hereditary forms of Parkinson's disease. Additionally, Vyant Bio, Inc. maintains a collaborative agreement specifically for the discovery of Parkinson's Disease therapies. The company's headquarters are located in Cherry Hill, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free